Alendronate versus alfacalcidol (1-alpha OH vitamin D)
( DrugBank: Alfacalcidol, Vitamin D / KEGG DRUG: Alfacalcidol )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 41 | Giant cell arteritis | 1 |
| 46 | Malignant rheumatoid arthritis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 50 | Dermatomyositis | 1 |
41. Giant cell arteritis
Clinical trials : 160 / Drugs : 183 - (DrugBank : 35) / Drug target genes : 32 - Drug target pathways : 125
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
46. Malignant rheumatoid arthritis
Clinical trials : 4,743 / Drugs : 3,042 - (DrugBank : 389) / Drug target genes : 205 - Drug target pathways : 253
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
50. Dermatomyositis
Clinical trials : 264 / Drugs : 298 - (DrugBank : 66) / Drug target genes : 71 - Drug target pathways : 173
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|